Key result
Higher NT-proBNP levels predicted all-cause mortality in dialysis patients under 75 years, but this prognostic association was reduced and not significant in patients aged 75 years or older.
Why the study?
The characterisation of NT-proBNP in chronic haemodialysis patients and its prognostic significance across age stratifications had not been evaluated.
Does baseline NT-proBNP predict mortality in chronic haemodialysis patients, and does this prognostic significance vary by age?
Cohort (n=1,316)
Yes
Does baseline NT-proBNP predict mortality in chronic haemodialysis patients, and does this prognostic significance vary by age?
While NT-proBNP is a strong predictor of mortality in younger haemodialysis patients, its prognostic utility is significantly reduced and loses statistical significance in patients aged 75 years or older.
Answers are grounded in this paper and cite their sources.
NT-proBNP should not yet guide mortality risk assessment in dialysis patients ≥75 years; leaves open age-specific prognostic utility for prospective validation.
Characterisation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in chronic haemodialysis patients and its prognostic significance in age stratification have not been addressed. A prospective cohort study with cross-sectional analyses at baseline was performed. Outcomes were all-cause mortality, non-malignancy-related mortality, and cardiovascular disease (CVD)-related mortality. NT-proBNP was significantly higher in elderly, female, and low dry weight patients. Study patients were divided into two groups: Group-O (≥75 years) and Group-Y (<75 years). The 7-year follow-up receiver operating curve analysis showed that NT-proBNP significantly predicted all outcomes. All-cause mortality cut-off points were significantly different among the groups (total cohort, 5375 pg/mL; Group-Y, 3682 pg/mL; Group-O, 11750 pg/mL). Cox regression analysis showed risks for all outcomes by tertile NT-proBNP significantly higher in the total cohort and Group-Y as adjusted by potential confounders. For all-cause mortality, hazard ratios and 95% confidence intervals (CI) were T2 1.70 (0.89 to 3.25), p = 0.11, T3 2.95 (1.54 to 5.67), p < 0.01 in Group-Y; and T2 1.00 (0.64 to 1.58), p = 1.00; T3 1.50 (0.94 to 2.40), p = 0.09 in Group-O. In conclusion, NT-proBNP was significantly higher in elderly, female, and low dry weight chronic dialysis patients. NT-proBNP was significantly associated with all outcomes. However, this association was reduced in elderly patients.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2019) conducted a cohort in Chronic haemodialysis (n=1,316). High NT-proBNP (Tertile 3) vs. Low NT-proBNP (Tertile 1) was evaluated on All-cause mortality in patients <75 years (Group-Y) (HR 2.95, 95% CI 1.54 to 5.67, p=<0.01). Higher NT-proBNP levels predicted all-cause mortality in dialysis patients under 75 years, but this prognostic association was reduced and not significant in patients aged 75 years or older.
Synapse has enriched 10 related papers. Consider them for comparative context: